Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients (Q36364200)

13 August 2017

1 reference

title

Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients (English)

1 reference

13 August 2017

2

Glenn J Treisman

1 reference

13 August 2017

Andrew F Angelino

1

1 reference

13 August 2017

publication date

1 December 2005

1 reference

International Review of Psychiatry

13 August 2017

published in

1 reference

13 August 2017

volume

17

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

471-476

1 reference

Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Thyroid and adrenal axis in major depression: a controlled study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Health assessment for chronic HCV infection: results of quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Differential effects of interleukin-1beta on neurotoxicity, cytokine induction and glial reaction in specific brain regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Psychiatric disorders among veterans with hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

An open-label trial of citalopram for major depression in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Plasma levels of citalopram in depressed patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Psychopathology, stress and HIV-risk injecting behaviour among drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

HIV risk behaviors and their relationship to posttraumatic stress disorder among women prisoners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression--a single case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Morbidity of chronic hepatitis C as seen in a tertiary care medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Bupropion for treatment of interferon-induced depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Hepatitis C and the correctional population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Epidemiology of hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500381567

10.1080/02646830500381567

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference